Bone Biologics Corp 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Bone Biologics Corporation on September 12, 2018. The Company is a Delaware corporation and has elected to be treated as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders considered and approved three proposals at the Annual Meeting:
- Proposal I (Election of Directors): All five nominees were elected. Don Hankey and Bret Hankey received unanimous support with no votes withheld. Bruce Stroever, Stephen LaNeve, and John Booth were elected with approximately 86% of votes cast in favor, while 874,246 votes were withheld for each.
- Proposal II (Executive Compensation): The advisory vote on executive compensation was approved with 5,424,971 "FOR" votes and 874,246 "AGAINST" votes.
- Proposal III (Auditor Ratification): The appointment of Weinberg & Company, P.A. as the independent registered public accountant for the fiscal year ending December 31, 2018, was ratified with 6,306,220 "FOR" votes and zero "AGAINST" votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the standard disclosure of the meeting results.
Key Facts for Investor Verification
- Verify the specific reasons for the 874,246 votes withheld for three of the five director nominees.
- Confirm the total number of shares outstanding to calculate the percentage of votes cast versus total equity.
- Review the definitive proxy statement filed on August 10, 2018, for detailed executive compensation data referenced in Proposal II.
- Monitor the Company's status as an emerging growth company and its election to use the extended transition period for financial accounting standards.